Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. Wu S, Liu F, Gai Y, Carter J, et al. Leuk Res 2024;144:107547.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu S, Liu F, Gai Y, Carter J, et al. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. Leuk Res 2024;144:107547.
PMID: 38968731